MX2016015092A - Inhibidor de proliferacion de celulas madre cancerosas. - Google Patents

Inhibidor de proliferacion de celulas madre cancerosas.

Info

Publication number
MX2016015092A
MX2016015092A MX2016015092A MX2016015092A MX2016015092A MX 2016015092 A MX2016015092 A MX 2016015092A MX 2016015092 A MX2016015092 A MX 2016015092A MX 2016015092 A MX2016015092 A MX 2016015092A MX 2016015092 A MX2016015092 A MX 2016015092A
Authority
MX
Mexico
Prior art keywords
cancer stem
growth inhibitor
stem cell
cell proliferation
stem cells
Prior art date
Application number
MX2016015092A
Other languages
English (en)
Inventor
Kurisaki Akira
Ying Wang Ying
Takada Hitomi
Ekimoto Hisao
Original Assignee
Nat Inst Advanced Ind Science & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Advanced Ind Science & Tech filed Critical Nat Inst Advanced Ind Science & Tech
Publication of MX2016015092A publication Critical patent/MX2016015092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención tiene como propósito principal proporcionar un inhibidor del crecimiento para las células madre cancerosas resistentes a las terapias con fármacos anticáncer existentes, inhibidor del crecimiento el cual actúa sobre las células a través de la inhibición del crecimiento y apoptosis. El inhibidor del crecimiento para las células madre cancerosas contiene un agonista de retinoide, preferiblemente tamibaroteno, solo o en combinación con un agonista de rexinoide, preferiblemente bexaroteno, como un componente efectivo. El inhibidor del crecimiento para las células madre cancerosas mejora los efectos de varios fármacos anticáncer cuando el inhibidor del crecimiento es usado en combinación con los fármacos anticáncer.
MX2016015092A 2014-05-21 2015-05-20 Inhibidor de proliferacion de celulas madre cancerosas. MX2016015092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014105543 2014-05-21
PCT/JP2015/064523 WO2015178426A1 (ja) 2014-05-21 2015-05-20 がん幹細胞の増殖抑制剤

Publications (1)

Publication Number Publication Date
MX2016015092A true MX2016015092A (es) 2017-05-09

Family

ID=54554092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015092A MX2016015092A (es) 2014-05-21 2015-05-20 Inhibidor de proliferacion de celulas madre cancerosas.

Country Status (12)

Country Link
US (2) US20170079942A1 (es)
EP (1) EP3146978B1 (es)
JP (1) JPWO2015178426A1 (es)
KR (1) KR20170005069A (es)
CN (2) CN106456770A (es)
AU (1) AU2015262349A1 (es)
CA (1) CA2949640A1 (es)
ES (1) ES2928499T3 (es)
MX (1) MX2016015092A (es)
RU (1) RU2016150116A (es)
TW (1) TW201607531A (es)
WO (1) WO2015178426A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
US20200268728A1 (en) * 2016-12-20 2020-08-27 Sumitomo Dainippon Pharma Co., Ltd. Drug targeting cancer stem cell
IT201800005072A1 (it) * 2018-05-04 2019-11-04 Nuovi farmaci prosenescenza
RU2702910C2 (ru) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения количества стволовых клеток рака молочной железы
RU2700695C2 (ru) * 2019-02-27 2019-09-19 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения клоногенной активности стволовых клеток рака молочной железы
WO2021261601A1 (ja) * 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
CA3203995A1 (en) * 2021-01-08 2022-07-14 David A. Roth Treatment regimens with fixed doses of tamibarotene
CN114045259B (zh) * 2021-11-08 2024-04-05 山东第一医科大学(山东省医学科学院) 一种抑制肿瘤干细胞的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227674A1 (en) * 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment

Also Published As

Publication number Publication date
EP3146978B1 (en) 2022-07-20
WO2015178426A1 (ja) 2015-11-26
KR20170005069A (ko) 2017-01-11
RU2016150116A3 (es) 2018-09-25
CN106456770A (zh) 2017-02-22
CA2949640A1 (en) 2015-11-26
AU2015262349A1 (en) 2017-02-02
TW201607531A (zh) 2016-03-01
US20170079942A1 (en) 2017-03-23
US20200061007A1 (en) 2020-02-27
RU2016150116A (ru) 2018-06-22
CN114392252A (zh) 2022-04-26
JPWO2015178426A1 (ja) 2017-04-20
EP3146978A1 (en) 2017-03-29
ES2928499T3 (es) 2022-11-18
EP3146978A4 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
MX2016015092A (es) Inhibidor de proliferacion de celulas madre cancerosas.
DOP2015000227A (es) Virus de la enfermedad de newcastle y usos de los mismos
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
DOP2017000124A (es) Agonistas parciales del receptor de insulina
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX2016007972A (es) Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
CR20150022A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150316A (es) Compuestos y sus métodos de empleo
AR095232A1 (es) Métodos y composiciones para el control de malezas
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2018004307A (es) Composiciones y metodos para modular la expresion de angiotensinogeno.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
TW201615060A (en) Organic light emitting device
UY35385A (es) ?métodos y composiciones para el control de malezas?.
MX2016005801A (es) Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.